Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer

Executive Summary

Merck KGaA/Pfizer's Bavencio is likely to be the first checkpoint inhibitor to gain approval in ovarian cancer but Roche's Tecentriq is hot on its heels. The ovarian cancer pipeline boasts seven other late-stage drugs, including antibody-drug conjugates and small molecules, that are ready to ramp up competition on the market.

Advertisement

Related Content

Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer
How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value
Merck KGaA/Pfizer's Bavencio Set To Enter Europe's Crowded I-O Market
Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
Triple Immunotherapy Combos Enter The Ovarian Cancer Fight
Pfizer Advances Avelumab In Ovarian Cancer With Syndax Combo Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel